May 24, 2012 – Exton, Penn. -
BioTrends Research Group, one of the world’s leading research and advisory firms for specialized biopharmaceutical issues, finds that, at four-months post-approval of Bayer/Janssen’s Xarelto to reduce the risk of stroke in patients with nonvalvular atrial fibrillation (AF)*, 39 percent of physicians have prescribed the drug to at least one of their AF patients for stroke prevention. Uptake is likely driven by its perceived advantages of once-daily dosing and lack of monitoring requirements. The recently published LaunchTrends®: Xarelto
report also highlights that the lack of a reversal agent and the risk of bleeding (including intracranial hemorrhage) are clinical disadvantages surveyed physicians mention most often for Xarelto.
It is interesting to note that uptake of Xarelto has been more rapid by the surveyed hospital-based cardiologists than internists. This may be explained by the fact that significantly more cardiologists than internists express awareness of Xarelto and recall being detailed by a Janssen sales representative, who are marketing Xarelto in the United States. Cardiologists and internists are typically prescribing Xarelto to AF patients at an intermediate and high risk of stroke, with patient share for Xarelto anticipated to increase over the next six months. Significantly more Xarelto prescribers have also been called on by a Janssen representative in the past month compared to non-prescribers.
Satisfaction with Xarelto is typically high among Xarelto prescribers. This is mirrored in BioTrends’ recently published TreatmentTrends®: Stroke Prevention in Atrial Fibrillation
report, which found that 90 percent of all surveyed physicians expressed a moderate or high overall level of satisfaction with Xarelto in the prevention of stroke associated with AF, second only to Boehringer Ingelheim’s Pradaxa. Pradaxa’s high overall satisfaction and performance ratings are not surprising considering that physicians perceive this therapy as performing best overall on efficacy attributes. However, it is interesting to note that Pradaxa’s performance overall on safety/tolerability attributes is rated lowest among anti-thrombotic therapies, largely driven by low ratings on availability of a reversal agent, use in patients with renal impairment and coagulation tests not being available to monitor therapeutic effects.
Unaided awareness of new products in development for stroke prevention in AF is low among respondents. Indeed, while 30 percent of cardiologists express awareness of products in development, primarily Bristol-Myers Squibb/Pfizer’s Eliquis, no internists report the same. TreatmentTrends: Stroke Prevention in Atrial Fibrillation also finds that cardiologists rate their initial reaction to Eliquis and the uniqueness of the product in comparison to other currently available agents for stroke prevention in AF significantly higher than internists. The majority of cardiologists and internists are also moderately or very willing to prescribe Eliquis to their AF patients for stroke prevention, likely due to its perceived advantages of overall safety, low bleeding risk and oral/convenient dosing schedule.
is a two-wave syndicated report series designed to track the uptake of Xarelto for stroke prevention in AF at four months and one year following its approval in stroke prevention in AF*. LaunchTrends assesses trial and use of new products, obstacles to use, reasons to use, typical patient types, product perceptions, promotional efforts/messages and product satisfaction. In the current wave of research, which measures Xarelto’s market impact at four months post-approval, BioTrends surveyed 50 hospital-based U.S. cardiologists and 52 hospital-based U.S. internists, and conducted qualitative interviews with a subset of 15 of the respondents in March and April 2012.
*Note, on July 1, 2011, the U.S. Food and Drug Administration (FDA) approved Xarelto to reduce the risk of blood clots, deep vein thrombosis and pulmonary embolism following hip or knee replacement surgery. On November 4, 2011, the FDA approved Xarelto to reduce the risk of stroke in patients with nonvalvular AF. This LaunchTrends: Xarelto report focuses on the impact of the stroke prevention in the AF indication.
TreatmentTrends®: Stroke Prevention in Atrial Fibrillation
report series is an annual syndicated report that provides a comprehensive view of the current and expected future management of stroke prevention in AF in the United States based on primary research with hospital-based cardiologists and internists. The survey was fielded in March 2012. TreatmentTrends: Stroke Prevention in Atrial Fibrillation
covers the use of anti-thrombotics for stroke prevention in AF, including Xarelto, Pradaxa, warfarin, aspirin and Bristol-Myers Squibb’s Plavix as well as attitudes and perceptions toward therapies, advantages and disadvantages, ideal patient types, barriers to growth and expected future use. In addition, respondents are queried about their awareness of and interest in products in development for stroke prevention in AF.